GSK3052230 has been shown to inhibit tumor growth in several cell line-derived xenograft and patient-derived xenograft (PDX) tumor models, including FGFR1-amplified lung cancer and FGFR2-mutated endometrial cancer models, and response to GSK3052230 positively correlated with overexpression of FGF2, FGF18, FGFR1c, FGFR3c, and ETV4 RNA levels [13]. This evidence concerns the gene FGF2 and lung cancer.